Pure Global
NCT05792540

Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders

Tanta University·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Depressive Disorder
Drug/Device/Intervention
Fluoxetine 20 mg
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Tanta University
Location
Tanta, Egypt
Timeline & enrollment
Phase
Phase 2
Start date
Jun 06, 2023
End date
Mar 20, 2025
Enrollment
75 participants
Primary outcome

• The primary endpoint is the change in Hamilton Rating Scale

Summary

Major depressive disorder (MDD) is a significant cause of disability that affects
 approximately 16% of the world's population and is associated with chronic inflammation.
 Although the mechanisms of MDD have not yet been clearly elucidated, NLRP3 inflammasomes have
 been implicated in the pathogenesis of depression.NLRP3 inflammasome is an intracellular
 multiprotein complex that consists of nod-like receptor protein 3, an adaptor protein, and a
 procaspase-1 precursor. It is well known that a variety of danger signals, such as
 pathogen-associated molecular patterns and danger-associated molecular patterns can activate
 NLRP3 inflammasome

ICD-10 classifications
Depressive conduct disorderRecurrent depressive disorder, unspecifiedRecurrent depressive disorderOther recurrent depressive disordersRecurrent depressive disorder, currently in remission
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05792540
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05792540 through Pure Global AI's free database. This Phase 2 trial is sponsored by Tanta University and is currently Recruiting. The study focuses on Depressive Disorder. Target enrollment is 75 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.